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Background: Recent years have seen a trend towards utilizing a video-assisted thoracic surgery (VATS)
approach for treatment of thymoma. Although increasing in practice, intermediate- and long-term
oncologic outcome data is lacking for the VATS approach. There is no oncologic data for the uniportal
VATS approach. We sought to evaluate the feasibility and impact on patient survival of uniportal VATS
thymectomy for early-stage thymoma.
Method: The clinical outcomes for 17 patients with Masaoka stage I to II thymomas treated between
January of 2009 and July of 2014 at a single institution were collected retrospectively. Primary endpoint was
overall survival (OS) and secondary endpoint was recurrence-free survival (RFS).
Results: Ten women and seven men underwent uniportal VATS thymectomy; eleven had stage I thymoma
and six had stage II thymoma. There were no conversions to open surgery. Operative mortality was zero.
Mean tumor size was 3.8±1.0 centimeters, with a range of 1.9 to 6.0 centimeters. All patients underwent a R0
resection. Five-year survival was 100%, and the estimated RFS was 100%.
Conclusions: Our findings suggest that uniportal VATS thymectomy for early-stage thymoma is feasible,
and the intermediate-term oncologic outcomes are comparable to historic standards for open and multiincision VATS thymectomy. However, additional follow-up is required to evaluate for long-term oncologic
outcomes.
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Introduction
Thymoma is a slow-growing tumor originating from the
epithelial cells of the thymus and remains the most common
anterior mediastinal neoplasm found in adults (1). Given
the rarity and indolent nature of this neoplasm, significant
controversy remains regarding the appropriate surgical
approach towards treatment of early stage thymoma (stage I
or II) (2-6).
Microscopically margin-negative resection has been well-
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established as the most important prognostic indicator of
overall- and recurrence-free survival (RFS) (4-10). Complete
surgical resection of early-stage thymoma has historically
resulted in excellent oncologic outcomes, with upwards
of 100% reported 5-year survival (2-8). While classically
performed through a median sternotomy, video-assisted
thoracic surgery (VATS) has been reported to achieve
equivalent oncologic outcomes (4-6,10-13). However, given
the indolent nature of this tumor, intermediate- and longterm data is still lacking with regards to the VATS approach.
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Figure 1 Two examples of the standard sub-three-centimeter incision utilized for our institution’s uniportal VATS thymectomy. VATS,
video-assisted thoracic surgery.

Single-incision, or uniportal, VATS thymectomy
has been reported (14-17), however, to date, no data
exists regarding intermediate-term oncologic outcomes.
Consequently, we retrospectively evaluated the overall
survival (OS) and RFS in all patients undergoing singleincision VATS thymectomy for early-stage thymoma at our
institution. We present the following article in accordance
with the STROBE reporting checklist, available at http://
dx.doi.org/10.21037/jtd-20-1370.
Methods
Study population and definitions
Between January 2009 and July 2014, a comprehensive
retrospective review of a prospectively collected thoracic
surgery database identified all patients who underwent
single-incision VATS thymectomy for early stage
thymoma. The study was conducted in accordance with
the Declaration of Helsinki (as revised in 2013). This study
was conducted with the approval of the Northwell Health
Institutional Review Board (October 6, 2017. IRB approval
#17-0659), consent was waived.
Clinical staging was based on computed tomography
(CT) and/or magnetic resonance imaging (MRI) findings.
No patients underwent preoperative biopsies. Final
pathological diagnosis was based on histology. Pathological
staging was based on the Masaoka staging system (18).
Histologic subtype was based on the World Health
Organization (WHO) classification system (8,9).
Exclusion criteria included all patients without stage I or
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II thymoma (e.g., late-stage thymoma (III and IV), thymic
hyperplasia, thymic carcinoma etc.). Size, in and of itself,
was not an exclusion criterion.
Surgical approach
All patients were operated upon by a single surgeon, at a
single institution. The preoperative plan was to perform
a unilateral single-incision (<3 cm incision; Figure 1)
VATS thymectomy, with conversion to open surgery
when clinically indicated. All specimens were removed via
an endoscopic retrieval bag (which helps to facilitate the
removal of large tumors once). Examples of a 5.2 and 9 cm
thymoma (Figure 2).
We remove all suspicious lymph nodes based on
preoperative imaging. Further, we perform en bloc
resection of the thymus, perithymic, prevascular, and
supradiaphragmatic lymph nodes. In addition, right
para-tracheal and para-aortic lymph nodes are dissected
when operating for advanced thymomas and/or thymic
carcinomas.
Surgical technique and instruments
All patients are placed in left lateral decubitus position
and secured to the bed, such that they can be placed at
a forty-five-degree angle with regards to the floor (our
preference is to utilize a bean-bag positioner with silk
tape placed across the hip). A single sub-three-centimeter
incision is created in the fifth intercostal space between
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B

Figure 2 Two separate images of resected thymomas via uniportal VATS thymectomy. (A) 5.2 cm thymoma; (B) 9 cm thymoma. VATS,
video-assisted thoracic surgery.

A

B

Figure 3 Example of our standard sub-three-centimeter incision (A) created in the fifth intercostal space between the mid- and anterior
axillary lines (ribs are numbered) and (B) affords enough space for simultaneous use of multiple instruments. PAL, posterior axillary line;
MAL, mid-axillary line; AAL, anterior axillary line.

the mid- and anterior-axillary lines (Figure 3A). This
incision affords enough space for simultaneous use of
multiple instruments (Figure 3B). For larger specimens,
the muscular portion of the incision may be extended,
however the extent of the skin incision does not need to
be enlarged. The operating surgeon positions himself
posterior to the patient, whereas the first assistant is
subsequently anterior to the patient.
A 5 mm thirty-degree angled thoracoscope provides
optimal visualization from phrenic nerve to phrenic
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nerve. Dissection is carried out utilizing standard VATS
instruments (curved and straight ringed forcep, curved
lymph node grasper, curved blunt-tip metal suction,
harmonic scalpel and endo Kittner). No SILS port or
wound-protectors were utilized.
All patients receive multi-level intercostal nerve block,
as well as multi-modality post-operative pain control
with non-steroidal anti-inflammatory (patient’s creatinine
clearance and bleeding are taking under consideration) and
narcotic-based, patient-controlled analgesia pump.
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Follow up
All patients had short-term follow up, usually within two
weeks of discharge from the hospital and then twice per
year for the first year. Given the nature of the disease, all
patients were encouraged to maintain yearly follow up
visits indefinitely (with requisite chest CT imaging prior
to follow up visits). If a patient were lost to follow up, the
electronic medical records were queried for proof of life.
No judgement was made regarding recurrence without
chest imaging and a follow-up visit with the thoracic
surgeon of record.
Data analysis
Our primary endpoint was OS and secondary endpoint was
RFS. Definitions of patient demographic characteristics,
perioperative variables, and postoperative outcomes were
obtained from the Society of Thoracic Surgeons Adult
Thoracic Surgery Database, version 2.81 (http://www.sts.
org/registries-research-center/sts-national-database/adultthoracic-surgery-database/data-collection).
Study data were collected and managed using REDCap
electronic data capture tools hosted at Long Island Jewish
Medical Center (19). REDCap (Research Electronic Data
Capture) is a secure, web-based application designed to
support data capture for research studies, providing: (I) an
intuitive interface for validated data entry; (II) audit trails
for tracking data manipulation and export procedures; (III)
automated export procedures for seamless data downloads
to common statistical packages; and (IV) procedures for
importing data from external sources.
The OS and RFS curves were calculated using the
Kaplan-Meier method.
Results
Patient demographics and operative data
Over the time period of the study, 21 patients underwent
elective, first-time, single-incisions VATS thymectomy.
Four patients did not meet inclusion criteria: three due to
advanced-stage disease (three stage III) and one secondary
to a pathologic diagnosis of thymic hyperplasia. Ultimately,
seventeen patients underwent resection for early-stage
thymoma. There were no documented islands or foci of
thymic carcinoma on final pathology. There were ten
females and seven males. The average age was 64.2±14.7
and only one patient had diagnosed myasthenia gravis.
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Patient demographics are summarized in Table 1.
Major intraoperative and perioperative data are reported
in Table 2. Eleven of the seventeen patients were classified
as stage I and six as stage IIA, according to the Masaoka
classification system. The mean surgical duration was
126.9±54.4 minutes. There were no conversions to open
surgery. All patients underwent a R0 resection. There were
no recorded phrenic nerve injuries in the entire cohort.
Clinical outcomes
For the entire cohort, 30-day mortality was 0.0% and
was without major perioperative surgical complications.
The median length of stay for the entire cohort was
1.0 days (range of 1.0–2.0 days), with a median follow-up of
65 months. Overall 5-year survival was 100% (Figure 4), with
Kaplan-Meier estimated 5-year RFS of 100% (Figure 5).
Short- and intermediate-term outcomes are summarized
in Table 3.
Discussion
Recent years have seen a trend towards utilizing a VATS
approach for treatment of thymoma (20), owing to the welldocumented advantages in perioperative outcomes of VATS
(6,11-13). While short-term outcomes have shown the
VATS approach to be effective (13,21), intermediate- and
long-term oncologic data is lacking in larger studies. More
recently, large multi-institutional studies from the Japanese
Association for Research on the Thymus (JART) (22),
the Chinese Alliance for Research in Thymomas (ChART) (23)
and the International Thymic Malignancies Group
(ITMIG) (24) have sought to address the previously
underpowered and short-term follow-up studies.
As it stands, the National Comprehensive Cancer
Network does not recommend VATS to be the standard
approach for routine resection of thymoma, however, with
regards to early-stage (I or II) disease, their stance states
“minimally invasive procedures may be considered for
clinical stage I–II if all oncologic goals can be met as in
standard procedures, and if performed by specialized centers
by surgeons with experience in these techniques (25).”
Several reports have shown single-incision VATS
thymectomy to be feasible (14-17), however, despite the
interest in single-incision thoracic surgery (14-17,26-28), to
date, no data exists regarding intermediate-term oncologic
outcomes. While technically feasible, critics will argue
that given the indolent nature of thymomas, definitive
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Table 2 Operative and perioperative data

Entire cohort (n=17)

Age, years

64.2±14.7

Variable

Entire cohort (n=17)

Masaoka tumor stage

Female gender

10 (58.8)

Stage I

11 (64.7)

Hypertension

5 (29.4)

Stage IIA

6 (35.3)

Dyslipidemia

8 (47.1)

Stage IIB

0 (0.0)

Cerebrovascular disease

0 (0.0)

Peripheral vascular disease

0 (0.0)

A

0 (0.0)

Diabetes mellitus

2 (11.8)

AB

9 (52.9)

Chronic obstructive pulmonary disease

0 (0.0)

B1

1 (5.9)

Current or prior smoking history

12 (70.6)

B2

5 (29.4)

Dialysis-dependent renal failure

0 (0.0)

B3

2 (11.8)

Myasthenia gravis

1 (5.9)

Values expressed are n (%) or mean ± standard deviation.

statements should be withheld for up to ten years (1-7).
However, as proponents of VATS have long-stated, since
the most statistically significant predictor of OS and RFS
remains extent of resection (2-6), as long as one adheres
to the tenets of oncologic standards, how the neoplasm is
removed should be of little consequence. Our data suggests
this to be true, as we achieved a R0 resection for the entire
cohort, and our 100% 5-year OS compares favorably to the
historic standards of Kondo et al. (n=769; 5-year OS: stage
I, 100%; stage II, 95%) (29), Murakawa et al. (n=96; 5-year
OS: stage I, 91%; stage II, 97%) (30), McCart et al. (n=21;
5-year OS: stage I, 98%%) (31) and Nakahara et al. (n=78;
5-year OS: stage I, 100%; stage II, 92%) (32). Although the
aforementioned studies did not report their 5-year RFS, our
100% estimated RFS would compare favorably if they had.
Not surprisingly, our data also compares favorably with
VATS studies which have reported 5-year OS: Sakamaki
et al. (n=71; 5-year OS: stage I, 94.1%; stage II, 94.7%) (12),
Pennathur et al. (n=18; estimated 5-year OS: stage I + II
100%) (33) and Chung et al. (n=24; 5-year OS: stage I+II,
100%) (34). Likewise, our 100% estimated 5-year RFS
compares favorably with that of Sakamaki et al. (n=71; 5-year
RFS: stage I, 94.1%; stage II, 85.4%) (12), Pennathur
et al. (n=18; estimated 5-year RFS: stage I+II 100%) (33)
and Chung et al. (n=24; 5-year RFS: stage I+II, 96%) (34).
As shown, single-incision VATS thymectomy for
the treatment of early-stage thymoma has favorable
intermediate-term oncologic outcomes as compared to the
historic standards of median sternotomy and more recent
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WHO classification

TNM tumor stage
Stage I

17 (100.0)

Stage II

0 (0.0)

Stage III (A or B)

0 (0.0)

Stage IV (A or B)

0 (0.0)

Conversions to open surgery
Duration of operation, minutes

0 (0.0)
126.9±54.4

Residual tumor classification
R0

17 (100.0)

Tumor size
Mean ± standard deviation, cm

3.8±1.0

Range, cm

1.9–9.0

Values expressed are n (%) or mean ± standard deviation.

multi-port VATS studies. This data lends support to the
feasibility of the single-incision VATS approach for the
treatment of early-stage thymoma.
While feasible, there remains no consensus regarding
strict contraindications for VATS. Kimura et al. reported
that tumors >5 cm substantially increased the risk of
capsular rupture and potential seeding of the tumor (35).
Alternatively, from their insights from the National Cancer
Database, Burt and colleagues did not find a correlation
between size and completeness of resection (20). Our
data suggest that tumor size is not a prognostic factor
with regards to extent of resection, with our entire cohort
undergoing a R0 resection. However, while no patients were
excluded from undergoing resection based on size, the high end
of our range was still 9.0cm. It is our institution’s belief that the
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ability to perform a sound oncologic procedure, not size, should
be the determining factor in choosing a surgical approach.

Probability of Survival

1
0.8
0.6
Uniportal VATS

0.4
0.2
0

0

1

Number at risk
17
17

2
3
Times (years)
17

17

4

5

17

17

Figure 4 Kaplan-Meier plot illustrating estimated 5-year overall
survival for patients undergoing uniportal VATS thymectomy.
Time from thymectomy (years) plotted on the x-axis. VATS, video-

Recurrence-free Survival

assisted thoracic surgery.

1
0.8
0.6
Uniportal VATS

0.4

Limitations
Our study has several limitations to be acknowledged.
Despite the fact that our data is comprehensive, our
sample size remains relatively small, and our analysis is
retrospective and largely observational in nature. Our
patient population was highly selected, consisting of those
individuals who presented with imaging consistent with
non-invasive disease; consequently, our results are not
generalizable to patients presenting with clinically more
advanced disease, such as stage III or IV thymoma. Given
the rarity of this neoplasm, large multi-institutional studies
are required, several of which are currently underway.
Our length of follow-up can still be considered short, as
recurrence has been seen upwards of ten years following
initial resection.1-7

0.2
0

0

1

Number at risk
17
17

2
3
Times (years)
14

12

4

5

12

12

Figure 5 Kaplan-Meier plot illustrating estimated 5-year
recurrence-free survival for patients undergoing uniportal VATS
thymectomy. Time from thymectomy (years) plotted on the x-axis.
VATS, video-assisted thoracic surgery.

Conclusions
In conclusion, our findings suggest that single-incision
VATS thymectomy for early-stage thymoma is feasible, and
the intermediate-term oncologic outcomes are comparable
to historic standards for open and multi-incision VATS
thymectomy. However, additional follow-up is required to
evaluate for long-term oncologic outcomes.

Table 3 Short-term and intermediate-term outcomes
Variable

Entire cohort (n=17)

30-day mortality

0 (0.0)

Stroke

0 (0.0)

Reoperation for bleeding

0 (0.0)

Sepsis of any cause

0 (0.0)

New renal failure requiring dialysis

0 (0.0)

Postoperative length of hospital stay, days, median (IQR)

1 (1 to 2)

Phrenic nerve injury

0 (0.0)

Diaphragmatic palsy

0 (0.0)

Follow up, mo, median (IQR)

65 (27 to 67)

5-year overall survival

17 (100.0)

KM estimated 5-year recurrence-free survival

17 (100.0)

Values expressed are n (%) or mean ± standard deviation, unless otherwise specified. mo, months; KM, Kaplan Meier.
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